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844-3 Comparative Outcomes of Percutaneous Coronary  
Interventions in Diabetics Versus Nondiabetics With 
Prior Coronary Artery Bypass Graft ing 
Verahese Mathew. Stephanie Wilson, Gregory W. Barsness, Robert L. Frye, Ryan 
Lennon, David R. Holmes, Jr., Mayo Clinic and Foundation, Rochester, Minnesota. 
Background: Randomized data suggests that coronary artery bypass graft (CABG) is 
superior to percutaneous coronary intervention (PCI) as an initial revasculadzation strat- 
egy in diabetics with multi-vessel coronary disease, although these data excluded 
patients with prior CABG. 
Methods: Patients with prior CABG undergoing PCI from January 1, 1996 through 
August 31, 2000 were divided into two groups based on whether or not they had diabe- 
tes, excluding patients with acute infarction or shock. Cox proportional hazards models 
were utilized to estimate the association between diabetes and adverse events. 
Results: 1,153 post-CABG PCI patients were identified (326 diabetics and 827 non-dia- 
betics). Diabetics were younger, more likely to have hypertension, heart failure, and 
lower ejection fraction. Procedural characteristics and angiographic and procedural suc- 
cess rates were similar. 
Diabetes was associated with increased mortality (hazard ratio (HR) 1.58, 95 % confi- 
dence intervals (CI) 1.10 - 2.27). Diabetes did not have a significant effect on mortality in 
patients treated for single territory coronary disease (HR 1.44, 95 % CI 0.69 - 3.02), but 
did in patients with multi-territory disease (HR 1.79, 95% CI 1.16-2.76). However, in dia- 
betics with multi-territory disease who were completely revascularized with PCI, mortality 
was comparable to non-diabetics (HR 1.32, 95 % CI 0.57 - 3.03). 
Conclusion: Among PCI patients with prior CABG, diabetes portends an adverse progno- 
sis, although diabetics treated for single territory coronary disease or multiple territory 
disease undergoing complete percutaneous revascularization had comparable survival 
to non-diabetics. 
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angiographical restenosis and clinical outcome as compared to cutting balloon angio- 
plasty. These results suggest that cutting balloon angioplasty with provisional stanting 
might be a better option for treating lesions in small coronary vessels in diabetic patients. 
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844-4 Impact  of  Diabetes on Out-of -Hospi ta l  Surv ival  
Following Percutaneous Coronary Intervention: A Case- 
Control Study 
Sean R. Wilson, Babak A. Vakili, Warren Sherman, Kumar L. Ravi, Timothy A. Sanborn, 
David L. Brown, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, 
New York. 
Background: Based upon data derived prior to the availability of coronary stants, diabet- 
ics are thought to have impaired survival following percutaneous coronary intervention' 
(PCI) compared to non-diabetics. We sought to determine whether diabetics continue to 
have greater mortality than non-diabetics following PCI performed in the era of wide- 
spread availability of coronary stints. 
Methods: Three hospitals in New York City contributed prospectively defined data ele- 
ments on 4400 consecutive patients undergoing PCI. From this data set, 851 diabetics 
were identified and matched for age, gender and extent of coronary disease to 851 non- 
diabetics. Mortality rates at a mean follow-up of 2.4 years were compared using Kaplan- 
Meier and Cox proportional hazards models. 
Results: In both groups the mean age was 63.4 years, 38% of patients were females, 
43% had 1 -vessel coronary artery disease (CAD), 32% had 2-vessel CAD and 24% had 
3-vessel CAD. Diabetic patients had a greater incidence of hypertension (77% vs. 71%, 
P=0.002), congestive heart failure on admission (7.6% vs. 3.7%, P=0.001), renal insuffi- 
ciency (4.2% vs. 1.6%, P=0.0O2) and dialysis (3.4% vs. 1.3%, P=0.004). Prior myocardial 
infarction (MI) was noted in 35% of both groups. An MI within 24 hours of PCI was diag- 
nosed in 5.5% of diabetics and 6.5% of non-diabetics (P=NS). The mean ejection fraction 
of diabetics was 50% compared to 51% for non-diabetics (P=0.005). Stents were placed 
in 77% of diabetics and 79% of non-diabetics (P=NS). GP lib/Ilia inhibitors were adminis- 
tered to 24% of diabetics and non-diabetics. Procedural success was 97% in both 
groups. In-hospital mortality was 0.8% for diabetics and 0.2% for non-diabetics 
(P=0.095). At a mean follow-up of 2.4 years, the mortality rate for diabetics was 14.2% 
compared to 6.8% for non-diabetics (Hazard Ratio: 1.73, 95% Confidence Interval 1.22- 
2.44, P=0.002). 
Conclusion: Diabetic patients continue to experience increased mortality compared to 
non-diabetics following PCI. Additional studies are required to define the optimal treat- 
ment of CAD in these patients. 
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844-5 Compar i son  With Coronary  Stent  and Cut t ing  Balloon 
in Smel l  Coronary  Vessels  in Diabet ic  Pat ients  
Katsuhiro Kawaauchi, Taizo Kondo, Tomomichi Suzuki, Yoshio Kakegawa, Yoshifumi 
Awaji, Komaki City Hospital, Komaki City; Japan. 
Background: Diabetic patients have an increased incidence of cardiac events and rest- 
enosis compared with non-diabetic patients after pemutaneous coronary interventions. 
The efficacy of coronary intervention for small vessels in diabetic patients is unknown. 
Methods: We performed elective coronary angioplasty using cutting balloon (CB) in 51 
diabetic patients, and stint in 35 diabetic patients, with a reference vssse~ <2.6ram in 
diameter. Chronic total occlusions, in-stent restenosis, rotational atherectomy followed by 
stanting were excluded in this study. Results: Stent group patients were older than CB 
group patients (66.0 vs. 61.0 years; p<0.01), There were no significant differences in 
other baseline clinical characteristics between two groups. QCA analysis and restenosis 
rate are presented below, Conclusions: In spite of better initial angiographic results, 
stinting in small vessels in diabetic patients does not provide any benefit in terms of 
Ctinical success 80.7% 97.1% 0.02 
Reference diameter, mm 2.22±0.27 2.20±0.25 NS 
De novo lesion 73.7% 68.6% NS 
Lesion length, mm 10.01 ±4.50 11.98±4.93 NS 
Pre MLD, mm 0.71±0.18 0.63±0.21 0.04 
Post MLD, mm 1.72±0.36 2.27±0.28 <0.0001 
F/U MLD, mm 1.19±0.50 1.19±0.53 NS 
Restanosis rate 31.7% 40.7% NS 
MACE, TLR (<6month) 31.7% 38.2% NS 
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844-6 Abnormal Hemoglobin Alc  Is Assoc ia ted  With an 
Increased Rate of Target Vessel Revascularization in 
Nondlabet ic  Pat ients  Undergoing Percutaneous 
Coronary  Revaacular lzat ion 
Roberto A. Comus. Jr.. Judith A. Boura, Steven C. Ajluni, William H. Devlin, Simon R. 
Dixon, Gerald C. "rimmis, William W. O'Neill, William Beaumont Hospital, Royal Oak, 
Michigan. 
Background: Prior studies have demonstrated that abnormalities in plasma glucose 
below the "diabetic range' of glycemia are associated with increased cardiovascular mor- 
tality in nondiabetic (nonDM) patients (pts). We examined the association between glyce- 
mic control as determined by hemoglobin Arc (Alc) and incidence of target vessel 
revascularization (TVR) in nonDM undergoing elective percutaneous coronary interven- 
tion (PCI). 
Methods: Baseline laboratory studies including Alc were drawn in 438 consecutive pts 
prior to elective PCI. NonDM pts were defined as pts without a history of diet or pharma- 
cologically controlled diabetes and At c < 7.0. Pts were followed for 1 year after the index 
PCI. 
Results: Of the 438 pts enrolled, 292 (66%) were nonDM. An abnormal Alc was found 
in 39% of nonDM. NonDM with Alc > 6.0% were more often male, had higher triglycer- 
ides and prior history of MI compared to nonDM with Alc < 6.0%. NonDM with Alc > 
6.0% had a similar rate of TVR compared to diabetic pts (p=NS), but a significantly 
higher rate of TVR compared to nonDM with Alc < 6.0% (p--0.002). 
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Conclusions: In nonDM pts undergoing PCI, the incidence of chronic hyperglycemia as 
determined by A lc> 6.0% is approximately 40%. Among nonDM, A lc> 6.0% is associ- 
ated with a significantly higher rate of TVR. These data suggest that screening for hyper- 
glycemia may be beneficial in pts undergoing PCI. Further studies are needed to 
determine if lifestyle modification and/or pharmacologic therapy would be beneficial in 
this high-risk population. 
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1148-1 Pulmonary Function Tests After Revascularization 
Gordon E. Pate. Michelle Agnew, Brandan Foley, Peter Craan, Finbarr O'Connell, 
Michael J. Walsh, Saint James's Hospital, Dublin, Ireland. 
Background: Percutaneous transiuminal coronary angioplasty (PTCA) and coronary 
artery bypass surgery (CABG) are almost equivalent in terms of symptom relief, compli- 
cations and mortality. The importance of non-cardiac effects of revascularisation, such as 
neuro-cognitive decline,is increasingly being recognized. 
Methods: This study examined the effects of PTCA on PFTs in 33 patients at six weeks 
and again at six months. This was compared with PFTs in 33 patients before and six 
months after CABG. 
Results: At six months after PTCA there was a drop in FEV1/FVC ratio from 78% to 76% 
(p<0.02) compared to baseline, due to a small increase in FVC (forced vital capacity) 
which was statistically significant at 6 weeks (+5%, p<0.03) but not at 6 months (+3%, 
p=0.23). There was a drop in FEF25-75% (-8%, p<0.05). There had been no significant 
changes in FEVl/FVC or FEF25-75% at six weeks. At neither six weeks nor at six 
months were there any statistically significant changes in FEVt (forced expiratory vol- 
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ume in one second), PEFR (peak expiratory flow rate), FEF 50% (forced expiratory flow 
at 50% of FVC), FIF50% (forced inspiratory flow at 50% of FVC), DLCO-SB (diffusing 
capacity of the lung to carbon monoxide-single breath technique), DLCO/VA (DLCO-SB/ 
alveolar ventilation ratio) or IVC (inspiratory vital capacity). 
Baseline characteristics were similar in the two groups but there were significantly more 
males and smokers in the surgical group (p < 0.01). Comparing baseline PFTs with those 
undergoing PTCA, the only significant differences were a 16.9% higher PEFR (p=0.04), a 
12.5% lower DLCONA (p=0.Ol), and a slightly lower BHT (1.9%, p=0.03) in the CABG 
group. At six months after surgery there were highly statistically significant reductions in 
FEV1, FVC, PEFR, FEF25-75%, FEF50% (all p<0.01), IVC, and DLCO-SB (p<0.03) of 
between 8 and 23% with a restrictive pattern. 
Conclusion: This study demonstrates that PTCA results in minimal disturbance of pulmo- 
nary function. It also confirms that the deleterious effects of coronary artery bypass sur- 
gery extend to six months. This post-surgical deterioration in pulmonary function should 
be taken into account when choosing between these revascularization techniques. 
1148-2 Impact of Peripheral Vascular Disease on In-Hospital 
Outcomes Following Percutaneous Coronary 
Intervention 
Babak A. Vakili, Stephen J. Green, Timothy A. Sanborn, James N. Slater, Warren 
Sherman, Kumar L. Ravi, David L. Brown, Albert Einstein College of Medicine/Montefiore 
Medical Center, Bronx, New York. 
Background: The presence of peripheral vascular disease (PVD) is associated with 
more extensive atherosclerosis and an increase in mortality from coronary heart disease. 
The impact of PVD on short-term outcomes following pemutaneous coronary intervention 
(PCI) is not well understood. 
Methods: Five hospitals in the New York City area contributed prospectively defined 
data elements on all patients undergoing PCI between January 1, 1998 and October 31, 
1999. We analyzed the effect of PVD on in-hospital outcomes following PCI using 
univadate and multivariate methods~ 
Results: Of 10,847 patients in the database, 803 (7.4%) had PVD. Patients with PVD 
were older (70 years vs. 63 years, P=O.001), more often female (34% vs. 30%, P=0.07) 
and more likely to be white (85% vs. 81%, P=O.02) than those without PVD. A history of 
diabetes (32% vs. 25%, P=0.O01 ), hypertension (81% vs. 72%, P=0.001), myocardial inf- 
arction (MI) (47% vs. 39%, P=0.001), stroke (10.3% vs. 3.1%, P=0.001), congestive 
heart failure (11.4% vs. 4.9%, P=0.001) and prior bypass surgery (23% vs. 9.8%, 
P=0.001) was more common in PVD patients. The mean ejection fraction was signifi- 
cantly reduced in PVD patients (42% vs. 45%, P=0.001) compared to those without PVD. 
Shock and hemodynamic instability was not increased in PVD patients. Left main coro- 
nary disease was more common in PVD patients (11% vs. 3.8%, P=0.001). The use of 
stents (73% vs. 82%, P=O.O01) was less common and atherectomy more common (15% 
vs. 11%, P=O.001) in PVD patients. Procedural success was 97% in both groups. Post- 
procedure complications including MI, stroke, stent thrombosis and abrupt closure did 
not differ between groups. In-hospital mortality was 1.4% among patients with PVD com- 
pared to 0.5% for those without PVD (P=0.0Ol). After adjustment for differences in clini- 
cal characteristics, the risk of in-hospital mortality for patients with PVD was 2.0 (95% 
Confidence Intervals: 1.01-4.0, P=0.04). 
Conclusion: Patients with PVD who undergo PCI are an extremely high-risk population. 
However, even after adjustment for their high-risk features, they maintain a 2-fold risk of 
in-hospital mortality. 
1148-4 Differences in Heparin Sensitivity Between Asians and 
Non-Asians 
Robert M. Minutello, Mun K. Hong, Manish Parikh, Geoffrey Bergman, Frank lacovone, 
S. Chiu Wong, New York Presbyterian Hospita/ - Come//Medical Center, New York, New 
York. 
Background: Access site bleeding complications can lengthen hospital stay and 
increase in peri-procedura[ morbidity and resource consumption. A significant proportion 
of these complications can be attributed to over-dosing of heparin. Clinical observations 
led us to hypothesize that Asians have a higher sensitivity to hepadn compared to non- 
Asians. 
Methods: In 106 patients, we prospectively administered a lower dose of hepadn to 
Asians (50 units/kg) compared to non-Asians (70 units,'kg) undergoing an elective PTCN 
stent procedure and compared peri-procedure activated clotting time (ACT) and in-hospi- 
tal bleeding. Patients with unstable angina, recent myocardial infarctions (<7 days) and 
those administered GP lib/Ilia inhibitors were excluded. 
Results: (See table.) There was no statistical difference in the baseline characteristics, 
the angiographic presence of thrombus, or the incidence of procedural complications 
between the two groups. The comparative results demonstrate that similar levels of ACT 
are achieved on average in Asians with significantly less heparin/kg. There is also a dif- 
ference in the average individual ACT to heparin/kg ratio, suggesting distinct dose 
response curves in the two groups. Using multiple linear regression, being Asian proved 
to be a significant explanatory variable in predicting ACT levels (p=.048). 
Conclusion: These findings suggest a higher sensitivity to heparin in Asians and a need 
to dose heparin lower in this population of patients. 
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1148-5 Ionic Contrast Substantially Increases the Activated 
Clot t ing  T ime in Patients Receiving Abciximab and 
Bivalirudin at the Time of Percutaneous Coronary 
Intervention 
Joel P. Reoinelli. Leslie Cho, Kent Dauterman, David Lee, A, Michael Lincoff, Cleveland 
Clinic Foundation, Cleveland, Ohio. 
Background: Ionic contrast possesses antithrombotic properties; however, the clinical 
significance of these effects remains contentious. In the setting of potent antiplatelet and 
antithrombin therapy during PCI, it remains unknown whether the use of ionic contrast 
results in a further increase in anticoagulation status. 
Methods: The first part of the ongoing REPLACE trial randomized 1056 PCI patients to 
receive either hepadn or bivalirudin as adjunctive antithrombotic therapy (the choice of 
contrast dye and glycoprotein lib/Ilia inhibition was left to the discretion of the attending 
physician). Our analysis compared the 396 available ACT values in patients who 
received ionic versus nonionic contrast, and then further stratified these patients accord- 
ing to the combination of antithrombotic and antiplatelet herapy they received. 
Results: The use of ionic contrast in PCI patients receiving adjunctive bivalirudin and 
abciximab was associated with a significant increase in the ACT (460± 189sec vs 348+ 
71sac, p=0.01 ). This additive effect of ionic contrast on ACT was not observed with other 
combinations of antithrombotic and antiplatelet herapies, (See Table) 
Conclusions: In PCI patients treated with abciximab and bivalirudin, the use of ionic 
contrast results in a significant prolongation of the ACT. This appears to represent a 
unique interaction between ionic dye, abciximab, and blvalirudin, and is not observed 
with other antiptateLet and antithrombotic ombinations. 
ACT Values (sec) 
Asian (n=55) Non-Asian (n=51) p-value 
ACT (sec) 282.4 _+ 63.5 292.9.1 _+ 48.6 0.33 
Heparin units/kg 52.4 _+ 17.2 70.0 _+ 17.8 <0.001 
ACT/Heparin units/kg 5.8 -+ 2.0 4.3 ± 0.9 <0.00t 
Ionic Nonionic P value 
Bivalirudin (all) (n=77) (n=319) NS 
395+/- 144 359+/-82 
Bivalirudin/ (n=29) (n=105) 
Abciximab 460+/-189 348+/-71 0.01 
Bivalirudin/ (n=t 9) (n=102) 
Eptifibatide 333+/-45 371+/-86 NS 
Heparin (all) (n=80) (n=322) 
288+#72 307+/-93 NS 
Hsparin/Abciximab (n=38) (n=92) 
293+/-86 286+/-106 NS 
Heparin/Eptifibatide (n=18) (n=108) 
295+/-53 317+/-94 NS 
1148-23 Frequency, Determinants, and Clinical Implications of  
Angiographically-Visible Intracoronary Thrombus 
Following Primary Angioplasty for Acute Myocardial 
Infarction 
Kishore J. Harjai, Cindy L. Grinss. Gregg W. Stone, Judith Boure, Hadsh Chandra, Mark 
Turco, Bruce Brodie, David Cox, Lorelei Gnnes, William W. O'NeilL Primary Angioplasty 
in Myocardial Infarction StudyGroup, William Beaumont Hospital, Royal Oak, Michigan. 
Background: in pts undergoing primary angioptasty (PAl for AMI, presence of intracor0- 
nary thrombus after intervention may reflect a severe prothrombotic tendency & could 
result in poor clinical OUtcome. 
Methods: In 2148 pts enrolled in PAMI-2, Stect PAMI, & PAMI No-Surgery-On-Site, we 
compared clinical & angiographic features of pts who had visible thrombus after PA (THR 
group, N=f 31) determined by core lab analysis, & those who did not. We assessed the 
impact of visible thrombus after PA on in-hospital & 1-yr outcomes in all pts & in the sub- 
set of pts with final TIMI-3 flow (N=1991). 
Results: THR pts were more likely to have Killip class > 1 (21 vs 13%) & had lower LVEF 
(46 vs 49%). They had greater diameter stenosis (94 vs 92%), & higher incidence of 
baseline thrombus (87 vs 62%) & TIMI-0 flow (75 vs 63%) in the culprit artery. During PA, 
they were less likely to receive ionic contrast (83 vs 91%) and stents (8 vs 35%), but 
more likely to receive lyrics (11 vs 5%) and ~ABP (19 vs 5%). After PA, THR pts had 
greater residual diameter stenosis (37 vs 19%), & less TIMI-3 flow (69 vs 94%) (p< 0.05 
for all). Multivariate correlates of THR after PA included presence of thrombus before PA 
& lack of stent use. During hospitalization, THR pts had similar mortality (3.8 vs 2.4%) but 
higher rate of MACE (death, reinfarction, or ischemic target vessel revascularization; 
10.7 vs 5.4%, p=O.01) than non-THR pts. During 1 yr follow-up, THR pts had higher mor- 
tality (9.2 vs 5.2%, p=0.05) but similar rate of MACE (23 vs 18%). In multivariate analy- 
ses, pt age, gender, baseline tachycardia, Killip class, LVEF, & initial TIMI flow, but not 
presence of THR after PA, were independently related to clinical outcomes. In the subset 
with final TIMI-3 flow, THR pts (n=89) had similar in-hospital death (1.1 vs 2.1%), & 
MACE (9.0 vs 5.2%), as well as 1-year death (6.1 vs 4.8%) & MACE (21 vs 17%) as non- 
THR pts (p=NS for all). 
Conclusions: 1. Visible intracoronary thrombus is uncommon after primary angioplasty, 
& is related to presence of thrombus before angioplasty & lack of stent use. 2. Post- 
angioplasty thrombus is a marker of worse in-hospital & 1-yr outcomes. However, the 
adverse prognosis of thrombus pts is related to their inferior baseline charactedstics. 
